SMAD6 and coronary artery disorder: We could, however, confirm a significant overrepresentation of SMAD6 null (loss-of-function) variants in CHD-APAH patients (2 in 32 CHD-APAH patients vs. 830 in 807,162 gnomAD v.4.1.0 individuals; p = 0.0005).